Advertisement

Picture EBD Group World of Partnering Opportunities 650x100px
Document › Details

Venturelab AG. (3/27/24). "Press Release: Venture Leaders Biotech 2024 – 10 Innovative Startups Selected for the Boston Roadshow".

Region Region Switzerland
Organisations Organisation Venturelab AG (CH)
  Organisation 2 InterAx Biotech AG
Products Product BIOTECH
  Product 2 Swiss Biotech Day 2024 Basel (SBD 2024)
Persons Person Montserrat, Jordi (Venturelab 202403 CEO + Co-Founder)
  Person 2 Chabria, Mamta (Tandem Therapeutics 202403 CEO + Co-Founder)
     


The Swiss National Startup Team welcomes new members: 10 startups have been selected for the Venture Leaders Biotech 2024. The entrepreneurs will meet international investors and industry leaders during their roadshow and access industry-specific expertise to grow their ventures.

Selected from over 70 applications by a jury of investors and biotech experts, the ten startups will join the roadshow in Boston, one of the world's most important life science hubs. From May 13 to May 17, 2024, the roadshow will connect the participants with international investors and industry leaders, accelerating their ventures' expansion in the US.

The Venture Leaders Biotech will introduce themselves and their startups at a kick-off event at the Swiss Biotech Day in Basel on April 22, 2024.

The startups will follow in the footsteps of high-flying former team members such as Covagen (acquired by Johnson & Johnson), Versantis (acquired by Genfit), SimplicityBio (acquired by Precision for Medicine), AMAL Therapeutics (acquired by Boehringer Ingelheim), NBE-Therapeutics (acquired by Boehringer Ingelheim), Alentis (USD 105 million funding round in 2023), and Interax Biotech (Seed round with US investors met during the roadshow). With the biotech industry comprising 39% of Swiss exports, the Venture Leaders Biotech program contributes to the enduring strength and vitality of the sector.

“Preparing for this roadshow for the 18th year is a tribute to the quality of innovation and startups that have been part of this journey,” shared Jordi Montserrat, Co-Founder and CEO of Venturelab. “I can’t wait to join this new edition and support this new team in their international expansion.”

"Thanks to our preparation during the roadshow, we engaged with VCs and pharma contacts, giving us invaluable exposure. Our team's mix of youth and experience taught us to thrive together," commented Mamta Chabria, Co-founder and CEO of Tandem Therapeutics and Venture Leaders Biotech 2023 participant.

Venture Leaders Biotech is organized by Venturelab in partnership with Swissnex in Boston and supported by Debiopharm, EPFL, ETH Zurich, Hansjörg Wyss, Kellerhals Carrard, Novartis, Swiss Biotech Association, and VISCHER.

Follow the entrepreneurs and the Venture Leaders Biotech roadshow on social media using the hashtag #VLeadersBiotech or on https://www.venturelab.swiss/venture-leaders-biotech.



About Venture Leaders

The Venture Leaders – Swiss National Startup Team members – have a clear goal: they want to take the first step towards international expansion, envisioning themselves as global players. Venturelab has 18 years of experience bringing Switzerland’s best entrepreneurs to the heart of technology hotspots: Silicon Valley, Boston, China, London, Barcelona, and Munich. Companies founded by the 500 Venture Leaders alumni have created more than 9,800 jobs and raised more than CHF 7.6 billion in capital. For more information, visit https://www.venturelab.swiss/ventureleaders.

Discover all the alumni here.


Adoram Therapeutics SA: Small molecule immunotherapy R&D at optimized lead stage

Adoram Therapeutics is a spin-off from the University of Geneva, discovering next generation small molecule therapies for cancer and inflammation based around GPCR drug targets, the largest class of r... Read more


Allegria Therapeutics AG: Therapeutics that modulate mast cell activity

Allegria Therapeutics is a Basel-based biopharma startup established in 2023 with a commitment to build a differentiated portfolio of therapeutic approaches around biological targets that modulate mas... Read more


EVIIVE: Next-generation liquid biopsy solution

Our startup specializes in the cutting-edge field of extracellular vesicle (EV) biomarker discovery, utilizing single EV analysis and machine learning to revolutionize precision medicine. We provide a... Read more


inSEIT AG: Enzyme immobilization for green industrial production

inSEIT (integral Service for Enzyme Immobilization Technologies) offers services focused on the screening, application and scaling up of enzyme immobilization to ensure the practical implementation in... Read more


KYLYS AESTHETICS SA: Revolutionizing Skin Filling Science

KYLYS AESTHETICS offers a biocompatible hyaluronan-based and thermosensitive dermal filler (Medical Device Class III) that has the ability to form microgel structures in the tissue, resulting in a lon... Read more


OBaris AG: OBaris provides a painless alternative to injectables.

Our unique platform aims at shifting the current paradigm from injectables to a simple, non-invasive formulation that enables safe and efficacious delivery of a variety of macromolecular drugs across ... Read more


Shape Biopharmaceuticals GmbH: Redefining Immunotherapy

At Shape, we’re pioneering a breakthrough in healthcare with proprietary engineered SHAPEnano particles, leveraging the immune system of patients to produce therapeutic antibodies directly inside thei... Read more


TissueLabs SA: The platform for creating organs and tissues in the lab.

TissueLabs is dedicated to building the platform for creating organs and tissues in the lab. We provide biomaterials, equipment, and services to support tissue engineering and regenerative medicine. O... Read more


Well Science AG: Natural immune support against allergic rhinitis

Founded in Freienbach, Switzerland in 2022, with support from the Nestlé R&D accelerator and the Swiss incubator firm Stryber, Well Science AG is on a mission to develop innovations to change the cour... Read more


Ymmunobio AG: First in class oncology drugs for unmet need

The incidence of gastric cancer is 1.1 M and only 1 in 5 respond to therapy. In addition, gastric cancer causes 770’000 deaths every year. We founded Ymmunobio in September 2021 in Riehen, Switzerland... Read more

Categories

   
Record changed: 2024-04-19

Advertisement

Picture Berlin Partner Top News Healthtech Company Mika 650x200px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Berlin Partner Top News Healthtech Company Mika 650x300px




» top